- Second Quarter 2022 Financial Results
- Revenue of $1,177 million
- Reported Net Loss of $22 million, Adjusted Net Income of $177 million
- Adjusted EBITDA of $300 million or 25.5% of Revenue
- Reported EPS of $(0.04), Adjusted EPS of $0.36
- Updating full year 2022 guidance to reflect current assumptions related to economic, environmental and company-specific factors impacting the business, expecting:
- Revenue of $4,465 to $4,550 million
- Reported diluted EPS of $(0.10) to $(0.03), Adjusted EPS of $1.06 to $1.13
- Reported Net Loss of $(48) to $(15) million, Adjusted EBITDA of $1,060 to $1,100 million
- Providing financial guidance for the third quarter 2022, expecting:
- Revenue of $1,010 to $1,060 million
- Reported diluted EPS of $(0.12) to $(0.06), Adjusted EPS of $0.12 to $0.18
- Reported Net Loss of $(61) to $(32) million, Adjusted EBITDA of $175 to $215 million
- Remain committed to achieve 60% adjusted gross margin and 31% adjusted EBITDA margin targets; extending timeline to achieve primarily due to significantly higher inflation, global macro uncertainties, and revenue mix changes.
- Net leverage ratio decreased to 5.3x adjusted EBITDA; Reduction to ~5.0x adjusted EBITDA expected by year-end 2022.
GREENFIELD, IN (August 8, 2022) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2022, provided guidance for the third quarter of 2022, and updated guidance for the full year 2022.
